Vergoeding 2015-2019 voor ATC-subgroep J05AP : Antivirale middelen voor behandeling van hcv-infecties
- Raming voor de totale Zvw-populatie
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| J05AP01 Ribavirine | 468.570 | 443.800 | 142.830 | 85.125 | 75.390 |
| J05AP03 Boceprevir | 5.191 | . | . | . | . |
| J05AP05 Simeprevir | . | 35.367 | . | . | . |
| J05AP07 Daclatasvir (Daklinza ®) | 18.067.700 | 24.202.200 | 6.061.800 | 838.270 | 11.424 |
| J05AP08 Sofosbuvir (Sovaldi ®) | 63.418.600 | 42.950.600 | 11.079.800 | 2.240.200 | 186.340 |
| J05AP09 Dasabuvir (Exviera ®) | 208.180 | 421.830 | 53.367 | 4.186 | . |
| J05AP51 Sofosbuvir met ledipasvir (Harvoni ®) | 10.313.600 | 57.094.600 | 18.910.700 | 7.163.400 | 1.093.500 |
| J05AP53 Ombitasvir met paritaprevir en ritonavir (Viekirax ®) | 2.971.700 | 5.615.900 | 737.490 | 84.546 | . |
| J05AP54 Elbasvir met grazoprevir (Zepatier ®) | . | . | 1.622.000 | 1.111.800 | 1.719.900 |
| J05AP55 Sofosbuvir met velpatasvir (Epclusa ®) | . | . | 11.148.200 | 14.319.800 | 4.983.400 |
| J05AP56 Sofosbuvir met velpatasvir en voxilaprevir (Vosevi ®) | . | . | . | 511.840 | 729.290 |
| J05AP57 Glecaprevir met pibrentasvir (Maviret ®) | . | . | . | 10.556.200 | 9.693.500 |
| Totaal | 95.453.541 | 130.764.297 | 49.756.187 | 36.915.367 | 18.492.744 |